OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Kevin Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 206-213
Open Access | Times Cited: 55
Kevin Winthrop, Peter Nash, Kunihiro Yamaoka, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 2, pp. 206-213
Open Access | Times Cited: 55
Showing 1-25 of 55 citing articles:
Herpes zoster: A Review of Clinical Manifestations and Management
Anant Patil, Mohamad Goldust, Uwe Wollina
Viruses (2022) Vol. 14, Iss. 2, pp. 192-192
Open Access | Times Cited: 285
Anant Patil, Mohamad Goldust, Uwe Wollina
Viruses (2022) Vol. 14, Iss. 2, pp. 192-192
Open Access | Times Cited: 285
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 107-118
Open Access | Times Cited: 92
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 1, pp. 107-118
Open Access | Times Cited: 92
Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
Shintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 11, pp. 1413-1424
Closed Access | Times Cited: 12
Shintaro Akiyama, Kaoru Yokoyama, Soichi Yagi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 11, pp. 1413-1424
Closed Access | Times Cited: 12
Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
David Fudman, Ryan McConnell, Christina Ha, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 454-468
Closed Access | Times Cited: 11
David Fudman, Ryan McConnell, Christina Ha, et al.
Clinical Gastroenterology and Hepatology (2024) Vol. 23, Iss. 3, pp. 454-468
Closed Access | Times Cited: 11
A Severe Case of Disseminated Herpes Zoster in a Patient With Crohn's Disease on Upadacitinib Who Completed the Recombinant Zoster Vaccine Series
Nicole Lue, Lauren K. Burdine, Tamara Kahan, et al.
ACG Case Reports Journal (2025) Vol. 12, Iss. 2, pp. e01599-e01599
Open Access | Times Cited: 1
Nicole Lue, Lauren K. Burdine, Tamara Kahan, et al.
ACG Case Reports Journal (2025) Vol. 12, Iss. 2, pp. e01599-e01599
Open Access | Times Cited: 1
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study
Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3358-3365
Open Access | Times Cited: 22
Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3358-3365
Open Access | Times Cited: 22
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Drug Safety (2021) Vol. 44, Iss. 5, pp. 515-530
Open Access | Times Cited: 36
Philip G. Conaghan, Eduardo Mysler, Yoshiya Tanaka, et al.
Drug Safety (2021) Vol. 44, Iss. 5, pp. 515-530
Open Access | Times Cited: 36
Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
Raimón Sanmartí, Héctor Corominas
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1734-1734
Open Access | Times Cited: 15
Raimón Sanmartí, Héctor Corominas
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1734-1734
Open Access | Times Cited: 15
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 10, pp. 1301-1312
Closed Access | Times Cited: 14
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 10, pp. 1301-1312
Closed Access | Times Cited: 14
Varicella-Zoster Meningitis and Myelitis After Herpes Zoster Dermatitis Treatment With Amenamevir: A Case Series and Literature Review
Satoru Tada, Yuta Kaito, Akihiro Watanabe, et al.
Cureus (2024)
Open Access | Times Cited: 5
Satoru Tada, Yuta Kaito, Akihiro Watanabe, et al.
Cureus (2024)
Open Access | Times Cited: 5
Novel insights into the management of rheumatoid arthritis: one year in review 2022
Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology (2022)
Open Access | Times Cited: 22
Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology (2022)
Open Access | Times Cited: 22
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
George Karpouzas, Zoltán Szekanecz, Eva Baecklund, et al.
Therapeutic Advances in Musculoskeletal Disease (2023) Vol. 15
Open Access | Times Cited: 13
George Karpouzas, Zoltán Szekanecz, Eva Baecklund, et al.
Therapeutic Advances in Musculoskeletal Disease (2023) Vol. 15
Open Access | Times Cited: 13
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years
Christina Charles‐Schoeman, Jon T. Giles, Nancy E. Lane, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 1, pp. 157-175
Open Access | Times Cited: 4
Christina Charles‐Schoeman, Jon T. Giles, Nancy E. Lane, et al.
Rheumatology and Therapy (2024) Vol. 11, Iss. 1, pp. 157-175
Open Access | Times Cited: 4
Current status of immunisation for herpes zoster
Anthony L. Cunningham, Kerrie J. Sandgren, Bruce Taylor
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Anthony L. Cunningham, Kerrie J. Sandgren, Bruce Taylor
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Development and validation of a sensitive LC-MS/MS assay for determination of upadacitinib in human plasma and its application in patients with inflammatory bowel disease
Jingjing Wu, Lang Lin, Jiajia Yan, et al.
Journal of Pharmacological and Toxicological Methods (2025) Vol. 131, pp. 107581-107581
Closed Access
Jingjing Wu, Lang Lin, Jiajia Yan, et al.
Journal of Pharmacological and Toxicological Methods (2025) Vol. 131, pp. 107581-107581
Closed Access
Complications virales des biothérapies/thérapies ciblées anti-inflammatoires
Lionel Piroth, Florian Moretto, Thibault Sixt, et al.
La Revue de Médecine Interne (2025)
Open Access
Lionel Piroth, Florian Moretto, Thibault Sixt, et al.
La Revue de Médecine Interne (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Advanced Therapy Screening in Inflammatory Bowel Disease and the Impact of Clinical Nurse Specialists: A Retrospective Analysis of Electronic Patient Records
Michael Colwill, Alison Ward, Kevin Jacob, et al.
Clinical Medicine (2025), pp. 100317-100317
Open Access
Michael Colwill, Alison Ward, Kevin Jacob, et al.
Clinical Medicine (2025), pp. 100317-100317
Open Access
Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study
Mohammad Movahedi, Angela Cesta, Xiuying Li, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0323229-e0323229
Open Access
Mohammad Movahedi, Angela Cesta, Xiuying Li, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0323229-e0323229
Open Access
Exploring the pharmacokinetic, toxicity and anti-arthritic activity of bioactive polyphenols to mitigate the HIF-regulated angiogenic-pannus growth in rheumatoid arthritis
Bharathi Kalidass, Abdul Azeez Nazeer, Malathi Mahalingam, et al.
International Immunopharmacology (2025) Vol. 158, pp. 114851-114851
Closed Access
Bharathi Kalidass, Abdul Azeez Nazeer, Malathi Mahalingam, et al.
International Immunopharmacology (2025) Vol. 158, pp. 114851-114851
Closed Access
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi∥, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Intestinal Research (2022) Vol. 21, Iss. 1, pp. 110-125
Open Access | Times Cited: 15
Toshifumi Hibi∥, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Intestinal Research (2022) Vol. 21, Iss. 1, pp. 110-125
Open Access | Times Cited: 15
Herpes zoster – Prävention, Diagnostik und Behandlung
Ricardo Niklas Werner, Kamran Ghoreschi
Der Hautarzt (2022) Vol. 73, Iss. 6, pp. 442-451
Closed Access | Times Cited: 15
Ricardo Niklas Werner, Kamran Ghoreschi
Der Hautarzt (2022) Vol. 73, Iss. 6, pp. 442-451
Closed Access | Times Cited: 15
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis
Michelle Bao, Juliana M. Kennedy, Michael T. Dolinger, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Michelle Bao, Juliana M. Kennedy, Michael T. Dolinger, et al.
Crohn s & Colitis 360 (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
